| http://www.w3.org/ns/prov#value | - Some trial data are available on antiplatelet, statin, and blood pressure (BP)???lowering FDCs, but these trials were mostly short-term and in populations with low to moderate CVD risk.3- 7 Despite recommendations,8 no evidence has been generated on benefits or risks of an FDC-based strategy among individuals with established CVD, for whom there is no contention about the indications for use of al
|
